Overview

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2020-03-20

Target enrollment:

Participant gender:

Summary

Niraparib is a PARP inhibitor. The study is a 2:1 randomized, double-blind, placebo-controlled, multi-center,phase 3 study of ZL-2306 (niraparib) as maintenance therapy following first-line platinum-based chemotherapy in patients with extensive-stage disease small cell lung cancer (ED-SCLC) to evaluate the efficacy and safety.

Phase:

Phase 3

Details

Lead Sponsor:

Zai Lab (Shanghai) Co., Ltd.

Treatments:

Niraparib